ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Aranesp Improved Anemia In MDS In Phase II Trial

September 30, 2005

Genomic Health Presents Meta-Analyses of Oncotype DX

January 28, 2011

In Brief: McIntyre New AACI President, Salmon President Elect; Hubbard NCI AD; Underleider CIB Chief

September 30, 1988

Diet & Nutrition, Carcinogenesis, Virus, Tobacco Committees Proposed For Elimination

May 6, 1977

ECOG, ACRIN Agree To Join; NCI’s Goal Of Four Adult Groups Is One Merger Away

March 18, 2011

Research Funding In Crisis; Scientists Fear Cancer Program’s Dismantling, AACR Says

January 20, 1995